Skip Navigation LinksHome > October 2013 - Volume 36 - Issue 5 > Androgen Deprivation Therapy and Definitive Radiotherapy for...
Text sizing:
American Journal of Clinical Oncology:
doi: 10.1097/COC.0b013e31821dee4e
Review Articles

Androgen Deprivation Therapy and Definitive Radiotherapy for Prostate Cancer

Mendenhall, William M. MD*,†; Henderson, Randal H. MD, MBA; Hoppe, Bradford S. MD, MPH; Nichols, Romaine Charles MD; Mendenhall, Nancy P. MD

Collapse Box


Adjuvant androgen deprivation therapy (ADT) improves outcomes of patients receiving definitive radiotherapy (RT) for local-regionally advanced prostate cancer. However, patients in most randomized trials had more advanced disease than observed in many practices and were treated with suboptimal RT doses. Although data are conflicting, long-term ADT likely has adverse side-effects in patients with comorbidities. We recommend 6 months of ADT monotherapy with gonadotropin-releasing hormone agonist and RT for patients with high-risk prostate cancer (≥T2c, Gleason Score 8 to 10, and/or prostate-specific antigen ≥20 ng/mL) with minimal or no comorbidities. Adjuvant ADT for unfavorable intermediate-risk patients with a Gleason Score of 4+3=7 is also reasonable.

© 2013 by Lippincott Williams & Wilkins, Inc


Article Tools


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.